Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 1 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Liselotte Sofie Hyveled  
2 Reason for the notification  
a) Position/status Member of the Board of Directors  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 2,028 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 2,028 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Liselotte Sofie Hyveled  
2 Reason for the notification  
a) Position/status Member of the Board of Directors  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 2,042 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 2,042 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen  
2 Reason for the notification  
a) Position/status President and CEO  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 131,760 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 131,760 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen  
2 Reason for the notification  
a) Position/status President and CEO  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 149,422 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 149,422 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 41,488 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 41,488 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 48,791 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 48,791 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 2,166 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 2,166 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Maziar Mike Doustdar  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 2,548 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 2,548 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Ludovic Helfgott  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 37,346 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 37,346 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Ludovic Helfgott  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 36,664 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 36,664 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Ludovic Helfgott  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 11,620 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 11,620 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Ludovic Helfgott  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 11,407 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 11,407 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 41,254 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 41,254 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Karsten Munk Knudsen  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 43,402 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 43,402 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 41,488 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 41,488 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 39,755 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 39,755 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 22,027 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 22,027 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 19,878 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 19,878 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa
2 Reason for the notification
a) Position/status Executive Vice President, head of North America Operations
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a) Description of the financial instrument,type of instrument, ADRs
  Identification code NVO
b) Nature of the transaction Purchase of ADRs
c) Price(s) and volume(s)        
  Price(s) Volume(s)  
  DKK 1,092.25 16.31 ADRs  
       
       
d) Aggregated information
  • Aggregated volume
  • Price
 16.31 ADRsDKK 1,092.25
e) Date of the transaction 2023-04-10
f) Place of the transaction New York Stock Exchange
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Douglas Langa
2 Reason for the notification
a) Position/status Executive Vice President, head of North America Operations
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a) Description of the financial instrument,type of instrument, ADRs
  Identification code NVO
b) Nature of the transaction Purchase of ADRs
c) Price(s) and volume(s)        
  Price(s) Volume(s)  
  DKK 1,275.49 10.42 ADRs  
       
       
d) Aggregated information
  • Aggregated volume
  • Price
 10.42 ADRsDKK 1,275.49
e) Date of the transaction 2023-09-01
f) Place of the transaction New York Stock Exchange
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Martin Holst Lange  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 16,780 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 16,780 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Martin Holst Lange  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 33,600 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 33,600 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Tania Sabroe  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 7,763 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 7,763 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Tania Sabroe  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 13,220 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 13,220 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Tania Sabroe  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 413 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 413 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Tania Sabroe  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Sale of shares  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 756.84 702 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 702 sharesDKK 756.84  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Nasdaq Copenhagen  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Marcus Schindler  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 16,780 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 16,780 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Marcus Schindler  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 33,600 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 33,600 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Camilla Sylvest  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 41,254 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 41,254 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Camilla Sylvest  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 43,402 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 43,402 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Henrik Ehlers Wulff  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 43,563 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 43,563 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Henrik Ehlers Wulff  
2 Reason for the notification  
a) Position/status Executive Vice President  
b) Initial notification/Amendment Initial notification  
3 Details of the issuer  
a) Name Novo Nordisk A/S  
b) LEI 549300DAQ1CVT6CXN342  
4 Details of the transaction(s)  
a) Description of the financial instrument,type of instrument, Shares  
  Identification code Novo Nordisk B DK0062498333  
b) Nature of the transaction Other transaction (transfer of shares inaccordance with Long Term Incentive programme)  
c) Price(s) and volume(s)          
  Price(s) Volume(s)    
  DKK 0.00 45,834 shares    
         
         
d) Aggregated information
  • Aggregated volume
  • Price
 45,834 sharesDKK 0.00  
e) Date of the transaction 2024-01-31  
f) Place of the transaction Outside a trading venue  

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:  
Ambre James-Brown +45 3079 9289abmo@novonordisk.com Elizabeth DeLuca (US)+1 609 580 9868edel@novonordisk.com
Investors:  
Daniel Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com Mark Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com  

Company Announcement No 8 / 2024

Attachment

  • CA240201-Insider-trading
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Novo Nordisk Charts.